DragonflyTherapeutics_Web.png

  • About

  • Platform

  • Inspiration

  • News

  • Careers

  • More

    • LinkedIn - White Circle
    • Twitter - White Circle
    • Facebook - White Circle
    CAREERS
    CONTACT US
    NEWS
    GET EMAIL UPDATES

    © 2018 All Rights Reserved

    Terms & Conditions

    Privacy

    We Use NK Cells to Kill Cancer

    At Dragonfly we invent therapies that harness the body's
    immune system, for vastly improved patient outcomes.

    THE LATEST AT DRAGONFLY THERAPEUTICS

    THE CHALLENGE

    iStock-506431238.jpg

    Cancer is the Leading Cause of Death Worldwide

    READ MORE
    Cell..jpg

    INSPIRATION

    Breakthrough Discoveries,  Renegade Scientists, and Patients Fighting Cancer
    That We Find Inspiring

    READ MORE

    OUR TECHNOLOGY

    3d-illustration-of-a-cancer-cell-and-lym

    Dragonfly's Proprietary TriNKETs Activate the Body's NK Cells and Mobilize T Cells + Other Cells of the Adaptive Immune System

    READ MORE

    Our Partners in the Fight to End Cancer

    celgene-logo.png
    UCBerk.png
    logo_vsm_3col-1.png
    u-chi.gif
    logo-mit-png-mit-logo-793.png
    Cornell-University.png
    UCSFHealthLogo17_radiology_white.png
    stanford-white.png
    MDA Logo.png
    DKFZ_Logo-3zu-Research_en_Black-Blue_sRG
    Signature_Stacked_Purple_Hex.png
    1280px-Merck_Logo.svg.png

    DRAGONFLY IN THE NEWS

    UNADJUSTEDNONRAW_mini_12d46.jpeg

    Dragonfly launches a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans. We have also partnered with Abbvie to work on cancer drugs as well as autoimmune diseases. 

    READ ALL NEWS